Differential gene expression profile between PC-14 cells treated with free cisplatin and cisplatin-incorporated polymeric micelles

Bioconjugate Chemistry

Volumn 14, Issue 2, 2003, Pages 449-457

  Nishiyama, Nobuhiro ^a   Koizumi, Fumiaki ^b   Okazaki, Soichiro ^a   Matsumura, Yasuhiro ^b   Nishio, Kazuto ^b   Kataoka, Kazunori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; DETOXIFICATION; FLAVONOIDS; GENE EXPRESSION; GENE EXPRESSION REGULATION; MICELLES; PRINCIPAL COMPONENT ANALYSIS; TARGETED DRUG DELIVERY;

CARRIER SYSTEMS; CIS-PLATIN; CISPLATIN; DIFFERENTIAL GENE EXPRESSIONS; GENE EXPRESSION PROFILES; POLYMERIC MICELLE; PRINCIPAL COMPONENTS; PROPERTY; SUSTAINED RELEASE; SYSTEMS POSSESSING;

MACROMOLECULES;

CISPLATIN; COMPLEMENTARY DNA; INTEGRIN; MATRIX METALLOPROTEINASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; POLYMER; PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL CYCLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DETOXIFICATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENE CONTROL; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MACROMOLECULE; METASTASIS; MICELLE; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PRINCIPAL COMPONENT ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TUMOR VASCULARIZATION; UNINDEXED SEQUENCE; UPREGULATION;

EID: 0037344002     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc025555t     Document Type: Article

References (53)

1. Ringsdorf, H. (1975) Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 51, 135-153.
2. Kataoka, K. (1996) Targetable polymeric drugs. Controlled drug delivery: the next generation (K. Park, Ed.) Chapt. 4, American Chemical Society, Washington D. C.
3. Kopecek J., Kopeckova, P., Minko, T., and Lu, Z.-R. (2000) HPMA copolymer-anticancer drug conjugate: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50, 61-81.
4. Gabizon, A. A. (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer. Res. 7, 223-225.
5. Maruyama, K., Ishida, O., Takizawa, T., and Moribe, (1999) K. Possibility and active targeting to tumor tissues with liposome. Adv. Drug Deliv. Rev. 40, 89-102.
6. Kwon, G., Suwa, S., Yokoyama, M., Okano, T., Sakurai, Y., and Kataoka, K. (1994) Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J. Controlled Release 29, 17-23.
7. Matsumura, Y., and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46, 6387-6392.
8. Matsumura, Y. (2001) Liposomes and micelles in cancer chemotherapy. Drug Delivery Syst. 16, 401-408.
9. Vasey, P. A., Kaye, S. B., Morrison, R., Twelves, C., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., Burtles, S., Fraier, D., Frigerio, E., and Cassidy, J. (1999) Phase I clinical and pharmacokinetic study of PK-1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer. Res. 5, 83-94.
10. Miyamoto, Y., and Maeda, H. (1990) Comparison of the cytotoxic effects of the high-and low-molecular weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res. 50, 1571-1575.
11. Miyamoto, Y., and Maeda, H. (1991) Enhancement by verapamil of neocarzinostatin action on multidrug-resistant Chinese hamster ovary cells: possible release of nonprotein chromophore in cells. Jpn. J. Cancer Res. 82, 351-356.
12. Omelyanenko, V., Kopeckova, P., Gentry, C., and Kopecek, J. (1998) Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Controlled Release 53, 25-37.
13. Minko, T., Kopeckova, P., and Kopecek, J. (1999) Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16, 986-996.
14. Minko, T., Kopeckova, P., and Kopecek, J. (2000) Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86, 108-117.
15. Huang, P., Feng, L., Oldham, E. A., Keating, M. J., and Plunkett, W. (2000) Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390-395.
16. 1. Cancer Res. 61, 7552-7555.
17. Nishiyama, N., Yokoyama, Y., Aoyagi, T., Okano, T., Sakurai, Y., and Kataoka, K. (1999) Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum(II) and poly(ethylene glycol)-poly(α, β-aspartic acid) block copolymer in an aqueous medium. Langmuir 15, 377-383.
18. Nishiyama, N., Kato, Y., Sugiyama, Y., and Kataoka, K. (2001) Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm. Res. 18, 1035-1041.
19. Harada, A., and Kataoka, K. (1995) Formation of polyion complex micelles in aqueous milieu from a pair of oppositely charged block copolymers with poly(ethylene glycol) segments. Macromolecules 28, 5294-5299.
20. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunological Methods 65, 55-63.
21. Rosenberg, B. (1978) Platinum complexes for the treatment of cancer. Interdiscip. Sci. Rev. 3, 134-147.
22. Ponzani, V., Bressolle, F., Haug, I. J., Galtier, M., and Blayac, J. P. (1994) Cisplatin-induced renal toxicity and toxicity-modulating strategies: review Cancer Chemother. Pharmacol. 35, 1-9.
23. Siddik, Z. H., Newell, D. R., Boxall, F. E., and Harrap, K. R. (1987) The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem. Pharmacol. 36, 1925-1932.
24. Avichechter, D., Schechter, B., and Arnon, R. (1998) Functional polymers in drug delivery: carrier-supported CDDP (cis-platin) complexes of polycarboxylates - effect on human ovarian carcinoma. React. Funct. Polym. 36, 59-69.
25. Bogdanov Jr., A., Wright, S. C., Marecos, E. M., Bogdanova, A., Martin, C., Petherick, P., and Weissleder, R. (1997) A long-circulating copolymer in "passive targeting" to solid tumors. J. Drug Targeting 4, 321-330.
26. Perez-Soler, R., Han, I., Al-Baker, S., and Khokhar, A. R. (1994) Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups. Cancer Chemother. Pharmacol. 33, 378-384.
27. Gianasi, E., Wasil, M., Evagarou, E. G., Keddle, A., Wilson, G., and Duncan, R. (1999) HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumor activity in vivo. Eur. J. Cancer 35, 994-1002.
28. Gonzalez, V. M., Fuertes, M. A., Alonso, C., and Perez, J. M. (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663.
29. Kartalou, M., and Essigmann, J. M. (2001) Mechanism of resitance to cisplatin. Mutation Res. 478, 23-43.
30. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997) Conservation of the Chh1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501.
31. Zhao, H., and Piwnica-Worms, H. (2001) ATR-mediated checkpoint pathway regulate phosporylation and activation of human Chk1. Mol. Cell. Biol. 21, 4129-4139.
32. Reed, E. (1999) Cisplatin, in Cancer Chemotherapy and Biological Response Modifiers (H. M. Pinedo, D. L. Longo, and B. A. Chanbner, Eds.) pp 144-151, Elsevier Science BV, Amsterdam.
33. Fisher, D. E. (1994) Apoptosis in cancer therapy: Crossing the threshold. Cell 78, 539-542.
34. Gottifredi, V., and Prives, C. (2001) Getting p53 out of the nucleus. Science 292, 1851-1852.
35. Momand, J., Wu, H.-H., and Dasgupta, G. (2000) MDM2-master regulator of the p53 tumor suppressor protein. Gene 242, 15-29.
36. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase 9 complex initiates an apoptotic protease cascade. Cell 91, 479-489.
37. Srinivasula, S. M., Ahmad, M., Fernades-Alnemri, T., and Alnemri, E. S. (1998) Autoactivation of procaspase-9 by Apaf-1 mediated oligomerization. Mol. Cell 1, 949-957.
38. Kojima, H., Endo, K., Moriyama, H., Tanaka, Y., Alnemri, E. S., Slapak, C. A., Teicher, B., Kufe, D., and Datta, R. (1998) Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J. Biol. Chem. 273, 16647-16650.
39. Delmastro, D. A., Li, J., Vaisman, A., Solle, M., and Chaney, S. G. (1997) DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 39, 245-253.
40. Rubin, E., Kharbanda, S., Gunji, H., Weichselbaum, R., and Kunfe, D. (1992) Cis-diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase c-dependent signaling pathway. Cancer Res. 52, 878-882.
41. Leppa, S., and Bohmann, D. (1999) Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18, 6158-6162.
42. Kharbanda, S., Yuan, Z. M., Weichselbaum, R., and Kufe, D. (1998) Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17, 3309-3318.
43. Agami, R., Blandino, G., Oren, M., and Shaul, Y. (1999) Interaction of c-Abl and p73a and their collaboration to induce apoptosis. Nature 399, 809-813.
44. Hardin, J. D., Boast, S., Schwartzberg, P. L., Lee, G., Alt, F. W., Stall, A. M., and Goff, S. P. (1996) Abnormal peripheral lymphocyte function in c-abl mutant mice. Cell. Immunol. 172, 100-107.
45. Nishio, K., Sugimoto, Y., Fujiwara, Y., Ohmori, T., Morikage, T., Takeda, Y., Ohata, M., and Saijo, N. (1992) Phospholipase c-mediated hydrolysis of phosphatidylcholine is activated by cis-diamminedichloroplatinum(II). J. Clin. Invest. 89, 1622-1628.
46. Maubant, S., Cruet-Hennequart, S., Poulain, L., Carreiras, F., Sichel, F., Luis, J., Staedel, C., and Gauduchon, P. (2002) Altered adhesion properties and alpha V integrin expression in a cisplatin-resistant human carcinoma cell line. Int. J. Cancer 97, 186-194.
47. Nista, A., Leonetti, C., Bernardini, G., Mattioni, M., and Santoni, A. (1997) Functional role of α4β1 and α5β1 integrin fibronetin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. Int. J. Cancer 72, 133-141.
48. Hoyt, D. G., Rusnak, J. M., Mannix, R. J., Modzelewski, R. A., Johnson, C. S., and Lazo, J. S. (1996) Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumour-derived endothelial cells. Cancer Res. 56, 4146-4149.
49. Zucker, S., Cao, J., and Chen, W.-T. (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650.
50. Heath, E. I., and Grochow, L. B. (2000) Clinical potential of matrix metalloproteinase inhibitors in cancer therapy. Drugs 59, 1043-1055.
51. Rihova, B., Jelinkova, M., Strohalm, J., St'astny, M., Hovorka, O., Plocova, D., Kovar, M., Draberova, L., and Ulbrich, K. (2000) Antiproliferative effect of a lectin- and anti-Thy-1, 2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with mouse Thy-1.2 gene. Bioconjugate Chem. 11, 664-673.
52. Kasuya, Y., Lu, Z.-R., Kopeckova, P., Minko, T., Tabibi, S. E., and Kopecek, J. (2001) Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates. J. Controlled Release 74, 203-211.
53. Parr, M. J., Masin, D., Cullis, P. R., and Bally, M. B. (1997) Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis Lung Carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Ther. 280, 1319-1327.